Highly-sensitive C-reactive protein, a biomarker of cardiovascular disease risk, in radically-treated differentiated thyroid carcinoma patients after repeated thyroid hormone withholding

Exp Clin Endocrinol Diabetes. 2013 Feb;121(2):102-8. doi: 10.1055/s-0032-1333230. Epub 2013 Feb 20.

Abstract

Aims: In patients radically treated for differentiated thyroid carcinoma, we assessed the response of highly-sensitive C-reactive protein, an inflammatory biomarker for cardiovascular risk, after thyroid hormone withholding ("deprivation"), as well as factors potentially influencing this response.

Material and methods: We included 52 adults (mean age 45.6±14.0 years, 35 females) who were disease-free after total thyroidectomy, radioiodine ablation and chronic thyroid hormone therapy. They were lifelong non-smokers without apparent inflammatory comorbidity, cardiovascular history beyond pharmacotherapy-controlled hypertension, anti-dyslipidemic medication, or C-reactive protein >10 mg/L in any study measurement. The index deprivation lasted ≥2 weeks, elevating serum thyrotropin >40 mIU/L or ≥100 × the individual's suppressed level. We examined the relationship of age, number of prior deprivations, and gender with the magnitude of post-deprivation C-reactive protein concentration through multivariable statistical analyses using the F test on linear regression models.

Results: Post-deprivation, C-reactive protein reached intermediate cardiovascular risk levels (based on general population studies involving chronic elevation), 1-3 mg/L, in 44.2% of patients and high-risk levels, >3 mg/L, in another 17.3%. Mean C-reactive protein was 1.77±1.50 mg/L, differing significantly in females (2.12±1.66 mg/L) vs. males (1.05±0.69 mg/L, P <0.001). In multivariable analysis, patients ≤45 years old (odds ratio, 95% confidence interval 0.164 [0.049-0.548]) were less likely, and females, more likely (3.571 [1.062-12.009]) to have post-deprivation C-reactive protein ≥1 mg/L.

Conclusions: Thyroid hormone withdrawal frequently elevated C-reactive protein to levels that when present chronically, were associated with increased cardiovascular risk in general population studies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Antithyroid Agents / adverse effects
  • Antithyroid Agents / therapeutic use
  • Biomarkers / blood
  • C-Reactive Protein / analysis*
  • Carcinoma / blood*
  • Carcinoma / immunology
  • Carcinoma / pathology
  • Carcinoma / therapy
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / immunology
  • Cell Transformation, Neoplastic / pathology
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Hormone Replacement Therapy
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk
  • Romania / epidemiology
  • Thyroid Gland / drug effects
  • Thyroid Gland / immunology
  • Thyroid Gland / pathology
  • Thyroid Gland / surgery
  • Thyroid Hormones / administration & dosage
  • Thyroid Hormones / therapeutic use
  • Thyroid Neoplasms / blood*
  • Thyroid Neoplasms / immunology
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / therapy
  • Thyroidectomy / adverse effects

Substances

  • Antithyroid Agents
  • Biomarkers
  • Thyroid Hormones
  • C-Reactive Protein